Immunome Inc (IMNM) USD0.0001
- Add to watchlist
- This stock can be held in a
Business summary
Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company’s portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, targeted effectors, radioligand therapies and ADCs. Its proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of antibodies and targets. Its lead discovery programs include Oncology (IMM-ONC-01) and SARS-CoV-2 (IMM-BCP-01). Its IMM-ONC-01 is its lead oncology program targets interleukin 38 (IL-38), which is a negative regulator of inflammation capable of promoting tumor evasion of the immune system. The Company is developing an antibody cocktail derived from the B cells of COVID-19 patients who exhibited high neutralizing titers. IMM-BCP-01 targets non-overlapping regions of the Spike protein of SARS-CoV-2, which include highly conserved, subdominant epitopes. The IMM-BCP-01 program is focused on the variants of SARS-CoV-2.
Contact details
Important dates
General stock information
- Short code:
- IMNM
- ISIN:
- US45257U1088
- Market cap:
- $1.20 billion
- Shares in issue:
- 53.25 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.